U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07244419) titled 'Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients' on Oct. 30, 2024.
Brief Summary: The investigators hypothesize that graft rejection after hematopoietic stem cell transplant (HSCT) is primarily driven by interferon gamma, and prophylactic interferon gamma inhibition in high-risk patients will prevent graft rejection. Additionally, knowledge of emapalumab PK/PD and in vitro mechanistic effects of emapalumab in this novel setting will guide optimization of dosing regimens and treatment approaches in future studies.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Hematopoieti...